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Regulators of G protein signaling (RGS) stimulate the
GTPase activity of G protein Ga subunits and probably
play additional roles. Some RGS proteins contain a Gg
subunit-like (GGL) domain, which mediates a specific
interaction with Gb5. The role of such interactions in
RGS function is unclear. RGS proteins can accelerate
the kinetics of coupling of G protein-coupled receptors
to G-protein-gated inwardly rectifying K1 (GIRK) chan-
nels. Therefore, we coupled m2-muscarinic acetylcho-
line receptors to GIRK channels in Xenopus oocytes to
evaluate the effect of Gb5 on RGS function. Co-expres-
sion of either RGS7 or RGS9 modestly accelerated GIRK
channel kinetics. When Gb5 was co-expressed with ei-
ther RGS7 or RGS9, the acceleration of GIRK channel
kinetics was strongly increased over that produced by
RGS7 or RGS9 alone. RGS function was not enhanced by
co-expression of Gb1, and co-expression of Gb5 alone
had no effect on GIRK channel kinetics. Gb5 did not
modulate the function either of RGS4, an RGS protein
that lacks a GGL domain, or of a functional RGS7 con-
struct in which the GGL domain was omitted. Enhance-
ment of RGS7 function by Gb5 was not a consequence of
an increase in the amount of plasma membrane or cyto-
solic RGS7 protein.
G protein-coupled receptors (GPCRs)1 form the largest fam-
ily of cell surface receptors and mediate cellular responses to
diverse signals that include neurotransmitters, hormones, and
sensory stimuli (1, 2). These receptors are proteins with seven
membrane-spanning regions and can interact with intracellu-
lar, heterotrimeric G proteins. When an agonist-bound or acti-
vated GPCR encounters a trimeric G protein, it catalyzes the
exchange of GTP for GDP at the a subunit of the G protein
(Ga). This leads to activation of the Ga and dissociation of the
activated GTP-bound Ga subunit from the Gbg dimer. Both the
activated GTP-bound Ga subunit and the freed Gbg dimers
regulate the activity of many intracellular effector molecules.
The intrinsic GTPase activity of Ga mediates signal termina-
tion. The Ga subunit hydrolyzes the bound GTP to GDP to
produce the inactive GDP-Ga subunit, which then reassociates
with high affinity to the Gbg dimer.
The intrinsic GTPase activity of purified Ga measured in
vitro is much slower than the rate of termination of many
cellular G protein responses such as phototransduction (3) and
ion channel modulation (4). This suggested that cells contained
factors that accelerated the GTPase activity of Ga. Subse-
quently, a new gene family called “regulators of G protein
signaling” (RGS) was identified (3, 5, 6). RGS proteins may
have several functions (7); one function of RGS proteins is to
serve as “GTPase-activating proteins” (GAPs) for Ga, hence to
accelerate signal termination. Swift transduction kinetics al-
low cells to read or detect rapidly changing concentrations of a
signaling molecule, while slow transduction kinetics cause
them to integrate or filter such a signal. Therefore, RGS pro-
teins are important components of the programs that deter-
mine how the temporal information specified in the release and
removal of an extracellular signaling molecule is translated
into an appropriate cellular response.
RGS proteins vary in size and sequence but all have a com-
mon, conserved core “RGS domain” of ;120 amino acids, which
is necessary and sufficient for their GAP activity. The RGS
family can be subclassified into small (160–220-residue) and
large (380–1400-residue) proteins. Small RGS proteins consist
largely of the RGS domain flanked by short N termini and even
shorter C termini. The larger RGS proteins contain additional
sequence-definable domains and motifs that predict interac-
tions with proteins other than Ga subunits (7). These addi-
tional domains underscore the current view that some RGS
proteins are not simply GAPs but have separate functions that
link them to other signaling pathways. For example, the RGS
protein p115RhoGEF acts as a GAP for Ga13 and as a GDP-
GTP exchange factor for the small GTPase RhoA (8, 9).
Sequence analysis has revealed that a subset of the large
RGS proteins, RGS6, -7, -9, and -11, contain a G protein g
subunit-like (GGL) domain between the N terminus and the
RGS domain (10, 11). This GGL domain allows these RGS
proteins to complex specifically with the atypical G protein b
subunit, Gb5 (10–12). Gb5 is significantly different from the
other Gb proteins in structure and cellular localization. Gb5
has only about 50% identity with Gb subunits 1–4, which
themselves are about 90% identical (13, 14). Gb5 is found
predominantly in neuronal tissues. Gb5-long, the long form of
Gb5, is found in the outer segment membranes of retinal pho-
toreceptors (14). Gb5-short, a shorter form of Gb5 is found in
brain and in the inner retina (13). Although the interaction of
Gb5 with the GGL domains of RGS proteins has been well
established, the effect of such interaction on RGS function is
presently uncertain. Levay et al. (12) reported that the forma-
tion of the Gb5-RGS7 complex blocked the binding of RGS7 to
the Gao subunit in purified preparations and concluded that
Gb5 is a specific RGS inhibitor (12). On the other hand, Snow
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et al. (10) showed that the complex between Gb5 and a partial
RGS11 construct (lacking a 200-amino acid stretch at the N
terminus) had GAP activity. In addition, recent work per-
formed with rod photoreceptor preparations indicates that the
RGS9-Gb5 complex is a GAP for transducin in the presence of
the effector, the g subunit of rod phosphodiesterase (15). How-
ever, the latter two studies did not compare the GAP activity of
the RGS-Gb5 dimer with that of the RGS protein alone (10, 15).
Thus, the effect of Gb5 on RGS function remains to be clarified.
A useful way to study the kinetics of the G protein cycle is to
follow the kinetics of activation and deactivation of G-protein-
gated inwardly rectifying K1 (GIRK) channels. GIRK channels
are heterotetrameric channels that are widely expressed in the
brain and in the heart and are activated by G protein-coupled
receptors, such as m2-muscarinic acetylcholine receptor (m2-
mAChR) and D2-dopamine receptor, that couple to pertussis-
sensitive G proteins (16). Free Gbg subunits that are released
from activated Ga G proteins activate or gate the GIRK chan-
nels (16). The key step in G protein signal termination occurs
when the GTPase activity of the Ga subunit hydrolyzes the
bound GTP to GDP. This produces the inactive GDP-Ga-G
protein that then reassociates with high affinity to the Gbg
dimer. Thus, the deactivation kinetics of the GIRK channels
are governed either by the rate of GTP hydrolysis by the Ga G
protein or by the rate at which Gbg subunits dissociate from
the GIRK channels. In atrial myocytes and in neurons, GIRK
currents activate and deactivate with time constants ,1 s after
application, and removal of receptor agonist occurs in less than
1 s (4, 17). When the channels were expressed in Xenopus
oocytes or other systems that have low endogenous levels of
RGS proteins, the currents recovered much more slowly, over
many seconds (18, 19). The rate was comparable with the rate
of GTP hydrolysis by purified Gai/Gao measured in vitro, sug-
gesting that that GTP hydrolysis determines the rate of chan-
nel deactivation. Two studies showed that the co-expression of
RGS proteins with receptors and GIRK channels in Xenopus
oocytes reconstituted the native kinetics of GIRK channels (18,
19). Point mutations in RGS2 designed to kill its GTPase ac-
celerating activity abolished RGS2 acceleration of GIRK inac-
tivation (20). These results suggest that RGS proteins acceler-
ate GIRK inactivation kinetics by enhancing the rate of GTP
hydrolysis by Ga. Whatever the mechanism, it is clear that the
time course of GIRK channel deactivation following the un-
binding of agonist from receptor may be used as a measure of
RGS function (21).
In this study, we expressed m2-mAChR and GIRK channels
with either RGS7 or RGS9 alone or in combination with Gb5 in
Xenopus oocytes. We observed an enhancement of RGS func-
tion in the presence of both forms of Gb5 and provide data to
suggest that the GGL domain is required for the enhancement
of RGS function by Gb5. We also showed that co-expressing
Gb5 did not alter the total concentration of RGS, indicating
that the enhancement of RGS function by Gb5 was not medi-
ated by an increase in the level of RGS protein.
EXPERIMENTAL PROCEDURES
Complementary cDNA Clones and cRNA Synthesis—cRNA was syn-
thesized in vitro from plasmids containing the cDNA and appropriate
promoters for cRNA transcription. Plasmids were linearized prior to
cRNA synthesis, and mMESSAGE MACHINE kits (Ambion) were used
to generate capped cRNA. The m2-mAChR receptor was provided by E.
Peralta (Harvard University). The cDNA for the GIRK subunits, rat
Kir3.1 (22) and mouse Kir3.2 (23), rat RGS4 (18), mouse RGS7, mouse
RGS9-2 (long striatally enriched form (24)), and mouse Gb5 short (13)
and long form (14) were generated in our laboratory.
Oocyte Culture and Injection—Xenopus oocyte preparation was de-
scribed previously (25). cRNA was injected into oocytes at a volume of
50 nl/oocyte using a Drummond microinjector. Oocytes were main-
tained in a saline buffer (96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 1 mM
CaCl2, and 5 mM HEPES, pH 7.5) solution supplemented with sodium
pyruvate (2.5 mM) and Gentamycin (50 mg/ml).
Electrophysiology—All oocytes were injected with 0.01 ng of cRNA for
the m2-mAChR and 0.02 ng of cRNA each for GIRK1 and GIRK2. 200
nM acetylcholine (ACh) was used as the m2-mAChR agonist. Receptor
activation was reversed by simultaneous ACh wash-off and perfusion
with the m2-mAChR antagonist, atropine (1 mM). A valve system con-
trolled by the data acquisition software, pCLAMP 6 (Axon Instru-
ments), was used to control solution changes and to minimize wash-in
and wash-out times. Two-electrode voltage clamp of the oocytes were
performed 36–72 h after cRNA injection. Membrane potential was
clamped at 280 mV using a Geneclamp 500 amplifier (Axon Instru-
ments) and pCLAMP 6 software. Electrodes were filled with 3 M KCl
and had resistances of 0.5–1.5 megaohms. To reveal inward currents
through the inwardly rectifying GIRK channels, recordings were per-
formed in oocyte saline buffer with elevated (16 mM) KCl concentration
(other components: 82 mM NaCl, 1 mM MgCl2, 1 mM CaCl2, and 5 mM
HEPES, pH 7.5).
Xenopus Oocyte Plasma Membrane and Cytosol Preparation—
Plasma membranes were separated mechanically as described (26).
Defolliculated oocytes were incubated for 10 min in ice-cold hypotonic
solution (5 mM NaCl, 5 mM HEPES, pH 7.5, 1 mM phenylmethanesul-
fonyl fluoride, 1 mM aprotinin, 1 mM leupeptin, and 1 mM pepstatin). The
plasma membranes together with the vitelline membranes (extracellu-
lar collagen-like matrix) were removed manually with fine tweezers and
appeared as transparent sheets. The remainder of the oocyte (cytosol),
consisting of cytoplasm and intracellular organelles, was left as an
intact sphere. The two fractions were pelleted separately by centrifu-
gation (10 min at 10,000 3 g and 4 °C) in a microcentrifuge. Previously,
it was shown by electron microscopy that the clear plasma and vitelline
membrane sheets were devoid of other cellular components (26).
Metabolic Labeling with [35S]Methionine and Immunoprecipita-
tion—After cRNA injection, 2 mCi/ml [35S]methionine was added to the
oocyte incubation solution, and the oocytes were incubated in this
solution for 36–48 h. Eight whole oocytes, 30 plasma membranes, or
eight cytosolic fractions were homogenized in 100 ml of SDS solubiliza-
tion buffer (4% SDS, 10 mM EDTA, 50 mM Tris, pH 7.5, 1 mM phenyl-
methanesulfonyl fluoride, 1 mM aprotinin, 1 mM leupeptin, and 1 mM
pepstatin) and boiled for 2 min. 900 ml of detergent containing immu-
noprecipitation buffer (190 mM NaCl, 6 mM EDTA, pH 7.5, 2.5% Triton
X-100, 1 mM phenylmethanesulfonyl fluoride, 1 mM aprotinin, 1 mM
leupeptin, and 1 mM pepstatin) was then added, and the homogenates
were centrifuged for 10 min at 10,000 3 g at 4 °C to remove insoluble
components. The supernatant was precleaned by incubation with pro-
tein A-Sepharose slurry for 3 h at 4 °C. The protein A-Sepharose slurry
was pelleted by centrifugation and discarded. 10 mg of an antibody to
RGS7 was added to each sample group and incubated at 4 °C for 16 h.
The RGS7 antibody, R4613, was raised in rabbit against recombinant
bovine RGS7. The antigen-antibody complex was captured by incuba-
tion with protein A-Sepharose for 4 h at 4 °C followed by centrifugation
(30 s at 10,000 3 g). The antigen-antibody-protein A-Sepharose pellets
were washed four times by resuspension and centrifugation in buffer
(150 mM NaCl, 6 mM EDTA, 50 mM Tris, pH 7.5, 0.1% Triton X-100, and
0.02% SDS). The supernatant was discarded each time. The pellets
were then boiled in SDS-gel loading buffer and subjected to SDS-
polyacrylamide gel electrophoresis. The protein bands were visualized
by autoradiography, and the relative intensities of the labeled bands
were measured using a PhosphorImager (Molecular Dynamics, Inc.,
Sunnyvale, CA) and ImageQuant (Molecular Dynamics) software.
Curve Fitting and Statistical Analysis—Kinetic analysis and curve
fitting were performed using pCLAMP 6 software. Exponentials were
fit to the activation and deactivation phases of the GIRK currents.
Cursors were positioned at points on the activation and deactivation
curves that corresponded to 20 and 80% of the maximum equilibrium
responses, and the exponentials were fitted to the portions of the
current trace between these two points. We used Student’s t test for
comparison of the independent means. Two-tailed p value , 0.01 is
defined as significantly different.
RESULTS AND DISCUSSION
We used ACh-evoked GIRK currents recorded from Xenopus
oocytes co-expressing the functional Kir3.1/Kir3.2 channel het-
eromultimer along with the m2-mAChR to define the role of the
G protein Gb5 subunit in RGS7 function. GIRK channels re-
spond to G protein activation and are useful for following G
protein kinetics and in turn as an assay for RGS function (21).
This analysis may also be physiologically relevant because the
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GIRK channel subunits used in this study, Kir3.1 and Kir3.2,
are widely distributed in the brain (27), and their expression
overlaps with the expression of RGS7 (28) and Gb5.
The expression of RGS7 modestly accelerated the deactiva-
tion kinetics of the GIRK response when compared with control
(Fig. 1, p , 0.01), reflecting a stimulation of the GTPase activ-
ity of the oocyte Ga-G proteins by RGS7. This acceleration has
been independently observed recently (28). In addition, we
found that co-expression of both the short and the long forms of
the G protein subunit Gb5 with RGS7 significantly accelerated
the speed of GIRK deactivation when compared with RGS7
alone (Fig. 1, p , 0.01).
We also found that Gb5 enhanced the function of another
GGL-containing RGS protein, the striatally enriched RGS9-2
(24). The expression of RGS9 with GIRK channels and m2-
mAChR accelerated GIRK channel kinetics (Fig. 2, p , 0.01).
Again, when we co-expressed Gb5, the acceleration of GIRK
channel kinetics was strongly increased over that produced by
RGS9 alone (Fig. 2, p , 0.01). Expression of Gb5 in the absence
of RGS7 or -9 had no effect on GIRK kinetics (Fig. 4, data not
shown), indicating that the Gb5 isoforms function to enhance
the action of these RGS proteins on Ga-G proteins. The func-
tional activity of RGS7 and RGS9 when expressed alone does
not appear to be due to any endogenous Gb5 expressed by
Xenopus oocytes. Oocyte lysates from uninjected oocytes
showed no immunoreactivity to an anti-Gb5 antibody that rec-
ognized Gb5 from Xenopus retina or Gb5 exogenously ex-
pressed in the oocytes by cRNA injection (data not shown).
These results appear to be at odds with those obtained by
Levay et al. (12), who showed that formation of the RGS7-Gb5
complex abolished the binding of RGS7 to purified Gao. Their
suggestion that Gb5 serves to inhibit RGS function differed
from the findings of Snow et al. (10), who showed that the
RGS11-Gb5 complex has GAP activity and hence must interact
with Ga. The discrepancy may have arisen because Snow et al.
(10) used a truncated RGS11 construct, while Levay et al. (12)
used full-length RGS7. Another explanation for the differing
results may be that Levay et al. (12) separately synthesized the
RGS protein and the Gb5 subunits in rabbit reticulocyte ly-
sates before allowing complex formation by mixing the two
reactions. The assumed RGS7-Gb5 complex prepared in this
manner may differ from the RGS7-Gb5 complex that is pro-
duced in the same cells, so that the former RGS7 conformation
may not correspond to that formed within the cell.
Biochemical studies have demonstrated that GGL domains
bind only Gb5 subunits (10–12) and not other Gb subunits.
Similarly, we found that the enhancement of RGS7 action was
specific to Gb5; co-expression of Gb1 did not increase the rate
FIG. 1. Effect of Gb5 and Gb1 on RGS7 function. Control oocytes
were injected with 0.01 ng of cRNA for the m2-mAChR and 0.02 ng of
cRNA each for GIRK1 and GIRK2. The other oocyte groups tested were
injected with the following cRNA combinations in addition to those
injected into the control oocytes: RGS7 (10 ng) alone, RGS7 (10 ng) and
Gb1 (10 ng), RGS7 (10 ng) and Gb5 short form (10 ng), and RGS7 (10
ng) and Gb5 long form (10 ng). A, normalized representative traces of
ACh (m2-mAChR agonist, 200 nM)-evoked and atropine (m2-mAChR
antagonist, 1 mM)-reversed GIRK currents recorded from the different
oocyte groups. The solid horizontal line above the traces represents ACh
application, while the dashed line shows atropine application. The
traces were normalized to the amplitude of the response just prior to the
application of atropine. B, comparison of the activation (1/tactivation,
solid black bars) and deactivation (1/tdeactivation, open bars) rate con-
stants derived from the exponential fits of the activation and deactiva-
tion phases of the GIRK currents in the different oocyte groups. All bars
are means 6 S.E. from 4–7 oocytes from the same oocyte donor. How-
ever, the results were repeated in oocytes from two other donors. The
mean steady-state current amplitudes in nA 6 S.E. for the different
oocyte groups were as follows: control, 271 6 51; RGS7 alone, 394 6 28;
RGS7 1 Gb1, 245 6 38; RGS7 1 Gb5 short, 351 6 88; RGS7 1 Gb5
long, 434 6 40.
FIG. 2. Effect of Gb5 on RGS9 function. Control oocytes were
injected with 0.01 ng of cRNA for the m2-mAChR and with 0.02 ng of
cRNA each for GIRK1 and GIRK2. The other oocyte groups tested were
injected with the following cRNA combinations in addition to those
injected into the control oocytes: RGS9 (alternatively spliced long or
striatally expressed form) (10 ng) alone or RGS9 (10 ng) plus and Gb5
short form (10 ng). A, normalized representative traces of ACh (m2-
mAChR agonist, 200 nM)-evoked and atropine (m2-mAChR antagonist,
1 mM)-reversed GIRK currents recorded from the different oocyte
groups. The solid horizontal line above the traces represents ACh ap-
plication, while the dashed line shows atropine application. The traces
were normalized to the amplitude of the response just prior to the
application of atropine. B, comparison of the activation (1/tactivation,
solid black bars) and deactivation (1/tdeactivation, open bars) rate con-
stants derived from the exponential fits of the activation and deactiva-
tion phases of the GIRK currents in the different oocyte groups. All bars
are means 6 S.E. from 4–7 oocytes from the same oocyte donor. The
mean steady-state current amplitudes in nA 6 S.E. for the different
oocyte groups were as follows: control, 414 6 26; RGS9 alone, 560 6 73;
RGS9 1 Gb5 short, 489 6 32.
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constant of GIRK activation or deactivation (Fig. 1). We tested
the integrity of the Gb1 cRNA that was used by coinjecting a
subset of the Gb1 cRNA receiving oocytes with Gg2. The acti-
vation of GIRK channels by G protein-coupled receptors is
mediated by Gbg dimers. As previously reported, the coinjec-
tion of cRNA for Gb1 and Gg2, but not Gg2 alone, resulted in a
dramatic increase in the basal activation of the GIRK channels
and an occlusion of further GIRK activation by coexpressed
m2-mAChR (data not shown) (29–31). This result verified that
functional Gb1 protein could be translated from the injected
cRNA transcript. In the example shown (Fig. 1B), it appears
that coinjection of Gb1 cRNA produces a small but significant
slowing of the action of RGS7 on GIRK deactivation kinetics.
This slowing may have resulted from a small decrease in RGS7
protein due to competition between RGS7 and Gb1 cRNA for
the oocyte protein translational machinery.
We then tested the effect of Gb5 on the function of RGS4,
which does not contain a GGL domain. Oocytes were injected
with two concentrations of RGS4 cRNA. Oocytes that were
injected with 30 ng of RGS4 cRNA displayed the fastest acti-
vation and deactivation of ACh-elicited GIRK currents. The
kinetics of the GIRK current response were significantly slower
in oocytes injected with 3 ng of RGS4 cRNA and slowest in the
control group. Coinjection of Gb5 cRNA into oocyte groups
injected with 3 ng of RGS4 cRNA did not significantly acceler-
ate the kinetics (Fig. 3). That Gb5 did not noticeably affect
RGS4 function was not due to an inability to measure faster
GIRK kinetics because the kinetics of GIRK activation and
deactivation were significantly accelerated in oocytes injected
with a higher amount of RGS4 cRNA (30 ng). Associated with
the extreme acceleration of the GIRK activation phase pro-
duced in the oocyte group injected with 30 ng of RGS4 cRNA is
a significant decay or sag of the current trace. This has been
observed previously and may reflect a desensitization process
that is normally obscured by slower rise times (18, 32).
We also tested the effect of Gb5 on the function of a mutant
RGS7 construct, RGS7DN, lacking the N terminus and the
GGL domain. Oocytes were injected with three concentrations
of RGS7DN cRNA. Oocytes that were injected with 3 ng of
RGS7DN cRNA displayed markedly accelerated activation and
deactivation of ACh-elicited GIRK currents. These rates ex-
ceeded 2 s21 and may have been limited by the exchange time
of our chamber; the rates were thus at least as great as those
observed with full-length RGS7 coexpressed with Gb5 or with
RGS4. Thus, removal of the N terminus and GGL domain may
allow RGS7 to function more efficiently. However, the major
point for the present experiments is that GIRK kinetics were
slower and well within the resolution of our chamber in oocytes
injected with 0.5 ng of RGS7DN cRNA, slower still in the group
injected with 0.1 ng of cRNA, and slowest in the control group
(Fig. 4, p , 0.01). Importantly, coinjection of Gb5 cRNA into
control oocytes or groups injected with either 0.1 or 0.5 ng of
RGS7DN cRNA did not significantly accelerate the kinetics
(Fig. 4). These data indicate that Gb5 cannot accelerate GIRK
kinetics when expressed alone and does not enhance the func-
tion of RGS proteins that lack GGL domains. Furthermore,
these data argue against the possibility that it is the RGS7-Gb5
complex that specifically interacts with the channel to acceler-
ate the kinetics.
In previous experiments on Xenopus oocytes and Chinese
hamster ovary cells, the co-expression of RGS proteins in-
creased the rate constants for both GIRK activation and deac-
tivation (18, 19, 28) and also did not change the steady-state
activation levels. We obtained similar results in our experi-
ments with RGS7, RGS9, and Gb5. The expression of RGS7
and RGS9 modestly enhanced the observed activation rate
constants when compared with control, and these observed
activation rate constants were further enhanced by co-expres-
sion of Gb5 (Figs. 1 and 2; p , 0.01). Accelerated activation
kinetics (an increase in 1/tactivation) are in fact an unsurprising
and necessary consequence of the accelerated deactivation ki-
netics (an increase in 1/toff 5 1/tdeactivation), because in most
kinetic formulations,
1/tactivation 5 1/ton 1 1/toff (Eq. 1)
Thus, point mutations introduced in RGS2 and RGS4 that
abolished their GTPase enhancing activity also resulted in the
loss of the property of these proteins to enhance both the
activation and deactivation kinetics of GIRK channels (20). The
surprising aspect of this and previous experiments (18, 19, 21)
is that the increased 1/toff does not lead to a decrease in steady-
state activation, since the predicted fraction of open channels ƒ
is given by the following.
ƒ 5 1/ton/~1/ton 1 1/toff! (Eq. 2)
In the most likely explanation for this increase in steady-
state currents, RGS proteins may be enhancing the rate of
GDP-GTP exchange as well as the rate of GTP hydrolysis (33).
We also explored mechanisms by which Gb5 might enhance
RGS7 function. In one possible mechanism, Gb5 would stabi-
lize the cellular conformation of RGS7, thereby increasing its
FIG. 3. Effect of Gb5 on RGS4 function. Control oocytes were
injected with cRNA for the m2-mAChR (0.01 ng) and 0.02 ng of cRNA
each for GIRK1 and GIRK2. The other oocyte groups tested were
injected with the following cRNA combinations in addition to those
injected into the control oocytes: RGS4 (30 ng), RGS4 (3 ng), Gb5 (10
ng), and RGS4 (3 ng). A, normalized representative traces of ACh (200
nM)-evoked and atropine (1 mM)-reversed GIRK currents. The solid
horizontal line above the traces represents ACh application, and the
dashed line shows atropine application. The traces were normalized to
the amplitude of the response just prior to the application of atropine.
B, comparison of the activation (1/tactivation, solid bars) and deactivation
(1/tdeactivation, open bars) rate constants derived from the exponential
fits of the activation and deactivation phases of the GIRK currents in
the different oocyte groups. All bars are means 6 S.E. from 4–6 oocytes,
all from the same oocyte donor. The mean steady-state current ampli-
tudes in nA 6 S.E. for the different oocyte groups were as follows:
control, 399 6 38; RGS4 (30 ng), 817 6 365; RGS4 (3 ng), 563 6 251;
RGS4 (3 ng) 1 Gb5 short, 900 6 97.
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cellular concentration. Precedent for such a mechanism is pro-
vided by the observation that Gb and Gg subunits are unstable
when unpaired and that co-expression of Gb and Gg subunits
results in higher cellular protein levels for both subunits (34–
36); this is also true for Gb5 (13). To determine whether Gb5
increases cellular levels of RGS7 protein, we used an anti-
RGS7 antibody to immunoprecipitate 35S-labeled RGS7 from
oocyte groups that had been tested electrophysiologically. The
immunoprecipitated RGS7 proteins were detected and quanti-
tated after SDS-polyacrylamide gel electrophoresis. Contrary
to our expectations, we found that neither the level of total nor
cytosolic RGS7 protein was increased by the co-expression of
Gb5 (Fig. 5). The failure to detect an increase in RGS7 levels
after co-expression of Gb5 was not due to saturation of either
the anti-RGS7 antibody or the detection technique, because the
amount of RGS7 detected was proportionally increased with
more starting material (data not shown). Similar results were
also obtained when the oocytes were lysed and the immunopre-
cipitations were performed in buffers containing no detergents,
suggesting that Gb5 did not enhance RGS7 function by altering
its solubility (data not shown).
Alternatively, Gb5 might enhance RGS7 function by target-
ing RGS7 to the plasma membrane, thus increasing the effec-
tive concentrations of RGS7 near the G protein. However, both
the long and short forms of Gb5 contain no predicted mem-
brane targeting sequences (13, 14). Instead, Gb subunits are
thought to associate with membrane by complexing to preny-
lated Gg subunits (37, 38). In accordance with the above argu-
ments, we detected no RGS7 signal in the oocyte plasma mem-
branes from any of the oocyte groups that were tested (Fig. 5).
RGS expression may be increased by Gb5 in other systems;
Snow et al. (11) reported that the protein levels of RGS6, which
also contains a GGL domain, were elevated in COS cells ex-
pressing Gb5. Consequently, it is notable that our data indicate
that Gb5 enhances the function of the GGL containing RGS7 in
the absence of changes in RGS7 protein expression. Instead, we
suggest that Gb5 may alter the conformation of the GGL con-
taining RGS proteins, thereby leading directly to enhanced
function. In support of this idea, it has previously been shown
that the conformations of monomeric Gb and Gg are altered
during dimerization (35, 36).
The principal findings of this study are severalfold. First, we
FIG. 4. Effect of Gb5 on function of an RGS7 construct lacking
the GGL domain. RGS7DN (corresponding to amino acids 322–470 of
the wild type clone) is an RGS7 construct created by deleting the
N-terminal region containing the GGL domain from the full-length wild
type mouse RGS7. Control oocytes were injected with cRNA for the
m2-mAChR (0.01 ng) and 0.02 ng of cRNA each for GIRK1 and GIRK2.
The other oocyte groups tested were injected with the following cRNA
combinations in addition to those injected into the control oocytes:
RGS7DN (3 ng), RGS7DN (0.5 ng), Gb5 short form (10 ng) and RGS7DN
(0.5 ng), RGS7DN (0.1 ng), Gb5 short form (10 ng) and RGS7DN (0.1
ng), Gb5 short form alone (10 ng). Comparison of the activation (1/
tactivation, solid bars) and deactivation (1/tdeactivation, open bars) rate
constants derived from the exponential fits of the activation and deac-
tivation phases of the GIRK currents in the different oocyte groups is
shown. All bars are means 6 S.E. from 4–6 oocytes, all from the same
oocyte donor. The mean steady-state current amplitudes in nA 6 S.E.
for the different oocyte groups were as follows: control, 1094 6 103;
control 1 Gb5, 573 6 32; RGS7DN (0.1 ng), 573 6 27; RGS7DN (0.1 ng)
1 Gb5 short, 820 6 169; RGS7DN (0.5 ng), 956 6 82; RGS7DN (0.5 ng)
1 Gb5 short, 651 6 48; RGS7DN (3 ng), 736 6 81.
FIG. 5. Effect of Gb5 on expression of RGS7 protein. Control
oocytes were injected with 0.01 ng of cRNA for the m2-mAChR and with
0.02 ng of cRNA each for GIRK1 and GIRK2. Other oocyte groups were
injected with the following cRNA combinations in addition to the cRNAs
injected into the control oocytes: RGS7 (10 ng) alone, RGS7 (10 ng), and
Gb5 short form (10 ng). A, autoradiograph showing [35S]methionine-
labeled RGS7 immunoprecipitated from cytosolic fraction (C) and
plasma membrane fraction (M). For experimental conditions, see “Ex-
perimental Procedures.” B, bar graph showing relative densities of the
RGS7 protein bands shown in A (see “Experimental Procedures”). Band
densities are expressed as a percentage of the density in the portion of
the control plasma membrane lane that corresponds to the RGS7 bands
in the RGS7-expressing samples. All bars are means 6 S.E. from three
separate experiments.
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have demonstrated that GIRK kinetics can be accelerated by
the co-expression of the GGL domain containing RGS7 and -9.
We have addressed uncertainties about the role of Gb5 in the
function of RGS proteins by demonstrating that Gb5 enhances
this action of both RGS7 and RGS9. We provide data to suggest
that the GGL domain is required for the enhancement of RGS
function by Gb5. We show that the enhancement of RGS7
function by Gb5 is not a result of an increase in the total,
cytosolic, or plasma membrane RGS7 protein concentration.
These results should assist our understanding of the role of
GGL-RGS proteins in modulating G protein signaling.
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